Literature DB >> 22365943

De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: a genomics approach to personalized medicine.

Ryan E O'Leary1, Jean C Shih, Keith Hyland, Nancy Kramer, Y Jane Tavyev Asher, John M Graham.   

Abstract

Monoamine oxidase A and B (MAOA and MAOB) play key roles in deaminating neurotransmitters and various other biogenic amines. Patients deficient in one or both enzymes have distinct metabolic and neurologic profiles. MAOB deficient patients exhibit normal clinical characteristics and behavior, while MAOA deficient patients have borderline intellectual deficiency and impaired impulse control. Patients who lack both MAOA and MAOB have the most extreme laboratory values (urine, blood, and CSF serotonin 4-6 times normal, with elevated O-methylated amine metabolites and reduced deaminated metabolites) in addition to severe intellectual deficiency and behavioral problems. Mice lacking maoa and moab exhibit decreased proliferation of neural stem cells beginning in late gestation and persisting into adulthood. These mice show significantly increased monoamine levels, particularly serotonin, as well as anxiety-like behaviors as adults, suggesting that brain maturation in late embryonic development is adversely affected by elevated serotonin levels. We report the case of a male infant with a de novo Xp11.3 microdeletion exclusively encompassing the MAOA and MAOB genes. This newly recognized X-linked disorder is characterized by severe intellectual disability and unusual episodes of hypotonia, which resemble atonic seizures, but have no EEG correlate. A customized low dietary amine diet was implemented in an attempt to prevent the cardiovascular complications that can result from the excessive intake of these compounds. This is the second report of this deletion and the first attempt to maintain the patient's cardiovascular health through dietary manipulation. Even though a diet low in tyramine, phenylethylamine, and dopa/dopamine is necessary for long-term management, it will not rescue the abnormal monoamine profile seen in combined MAOA and MAOB deficiency. Our patient displays markedly elevated levels of serotonin in blood, serum, urine, and CSF while on this diet. Serotonin biosynthesis inhibitors like para-chlorophenylalanine and p-ethynylphenylalanine may be needed to lower serotonin levels in patients with absent monoamine oxidase enzymes.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365943      PMCID: PMC3468330          DOI: 10.1016/j.ejmg.2012.01.007

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  21 in total

1.  Increased stress response and beta-phenylethylamine in MAOB-deficient mice.

Authors:  J Grimsby; M Toth; K Chen; T Kumazawa; L Klaidman; J D Adams; F Karoum; J Gal; J C Shih
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  Improved screening procedure for biogenic amine production by lactic acid bacteria.

Authors:  S Bover-Cid; W H Holzapfel
Journal:  Int J Food Microbiol       Date:  1999-12-01       Impact factor: 5.277

3.  p-ethynylphenylalanine: a potent inhibitor of tryptophan hydroxylase.

Authors:  A H Stokes; Y Xu; J A Daunais; H Tamir; M D Gershon; P Butkerait; B Kayser; J Altman; W Beck; K E Vrana
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.

Authors:  H G Brunner; M Nelen; X O Breakefield; H H Ropers; B A van Oost
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

5.  A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior.

Authors:  Kevin Chen; Daniel P Holschneider; Weihua Wu; Igor Rebrin; Jean C Shih
Journal:  J Biol Chem       Date:  2004-07-22       Impact factor: 5.157

6.  Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes.

Authors:  F A Collins; D L Murphy; A L Reiss; K B Sims; J G Lewis; L Freund; F Karoum; D Zhu; I H Maumenee; S E Antonarakis
Journal:  Am J Med Genet       Date:  1992-01-01

7.  Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA.

Authors:  O Cases; I Seif; J Grimsby; P Gaspar; K Chen; S Pournin; U Müller; M Aguet; C Babinet; J C Shih
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

8.  Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.

Authors:  J W Lenders; G Eisenhofer; N G Abeling; W Berger; D L Murphy; C H Konings; L M Wagemakers; I J Kopin; F Karoum; A H van Gennip; H G Brunner
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

9.  X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism.

Authors:  H G Brunner; M R Nelen; P van Zandvoort; N G Abeling; A H van Gennip; E C Wolters; M A Kuiper; H H Ropers; B A van Oost
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

10.  Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.

Authors:  A B Alfieri; L X Cubeddu
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  6 in total

1.  XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing.

Authors:  Amélie Piton; Claire Redin; Jean-Louis Mandel
Journal:  Am J Hum Genet       Date:  2013-07-18       Impact factor: 11.025

Review 2.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

3.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

4.  20 ans après: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition.

Authors:  Amélie Piton; Hélène Poquet; Claire Redin; Alice Masurel; Julia Lauer; Jean Muller; Julien Thevenon; Yvan Herenger; Sophie Chancenotte; Marlène Bonnet; Jean-Michel Pinoit; Frédéric Huet; Christel Thauvin-Robinet; Anne-Sophie Jaeger; Stéphanie Le Gras; Bernard Jost; Bénédicte Gérard; Katell Peoc'h; Jean-Marie Launay; Laurence Faivre; Jean-Louis Mandel
Journal:  Eur J Hum Genet       Date:  2013-10-30       Impact factor: 4.246

5.  Monoamine oxidase A and A/B knockout mice display autistic-like features.

Authors:  Marco Bortolato; Sean C Godar; Loai Alzghoul; Junlin Zhang; Ryan D Darling; Kimberly L Simpson; Valentina Bini; Kevin Chen; Cara L Wellman; Rick C S Lin; Jean C Shih
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-31       Impact factor: 5.176

6.  A proposed nosology of inborn errors of metabolism.

Authors:  Carlos R Ferreira; Clara D M van Karnebeek; Jerry Vockley; Nenad Blau
Journal:  Genet Med       Date:  2018-06-08       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.